Experimental cocktail aims to shrink liver tumors in tough colorectal cancer
NCT ID NCT07128355
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This pilot study is testing whether combining two immunotherapy drugs (botensilimab and balstilimab) with precise, high-dose radiation (SBRT) can safely treat colorectal cancer that has spread to the liver and is not responding to standard chemotherapy. The study will enroll 15 adults whose cancer is a specific type called non-MSI-H or pMMR. The main focus is on safety, but researchers will also check if the treated liver tumors shrink.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Botensilimab and balstilimab (immunotherapy drugs) plus stereotactic body radiation therapy (SBRT)
- What this could lead to
- If successful, this combination could offer a new treatment option for people with a hard-to-treat form of colorectal cancer that has spread to the liver.
- What could go wrong
- This is a very early, small pilot study with only 15 people, so results may not apply broadly. The main goal is safety, not effectiveness, and there is a risk of serious side effects from the radiation or immunotherapy.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-MSI-H OR PMMR COLORECTAL CANCER WITH LIVER METASTASIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Massachusetts General Hospital
RECRUITINGBoston, Massachusetts, 02114, United States